Laser therapeutic apparatus

 

(57) Abstract:

The invention relates to medical equipment and can be used in the apparatus for non-invasive therapeutic effects of laser radiation on the pathologic lesion. The apparatus contains laser of visible range of the radiation, the output of which has a polarizer return dichroic mirror, tunable to wavelengths of laser dyes in a solid matrix, the cavity which contains the Cam device type, providing rotation of the active element together with his swing on the spiral of Archimedes with a constant linear velocity, and a system for the transmission of laser radiation on biological object. The present invention allows to increase the spectral and energy efficiency of the laser radiation during therapeutic effect while reducing the time of exposure and to increase the durability of the apparatus. 1 Il.

The invention relates to laser medical and biological engineering.

Known laser therapeutic equipment containing gas continuous (for example, helium-neon) [1], and pulse - periodic lasers (e.g., semiconductor) is O. The disadvantage of this design is that the irradiation of the biological object is at a fixed wavelength, and, therefore, significantly reduced therapeutic effect of radiation depending on the individual susceptibility of the patient.

Also known biomedical apparatus containing a copper vapor laser as a source of visible radiation, the output of which is an additional laser solutions of organic compounds (dyes), working with pulse repetition rate of 8 kHz in the spectral range 550 - 750 nm [3].

The disadvantage of this design is the low stability of the energy characteristics of the laser radiation due to the convective instability of solutions of organic dyes. In addition, solutions of organic dyes (working concentration) have insufficiently high photo resistance, which significantly affects their persistence (because the solutions are prepared in advance and stored in sealed cuvettes) and life (durability). As a result, the operator is forced to perform additional operations to prepare the installation to work before each treatment session.

The closest solution from WPI who I harmonic ( = 532 nm) laser on the grenade), the output of which is installed basiccontrol laser dyes in a solid matrix, and the channel transmission of laser radiation on biological object [4].

Used as the active element of the solid matrix is a polymethyl methacrylate disk with evenly distributed along the volume of the organic dye rhodamine 6g, rhodamine s, oxazin 17, prolamin 510, oxazin 1, or crystals Li F with stable F2+the centers. This ensures individual selection mode of therapeutic effects in the wavelength range 550 - 1040 nm.

Operability is ensured introduced into the cavity of the laser dye system for rotating a solid matrix, performing the scanning of the laser beam visible range on the surface of the solid matrix, and the rotation speed (V) and the aperture of the scanned beam () are related by the equation:

V = f /2 R,

where f is the pulse repetition frequency of the laser radiation of the visible range,

a R is the radius of rotation of the solid matrix.

The disadvantage of the prototype is the low spectral and energy efficiency of laser radiation due to the influence of both polarization and IR - Spa is the s time of therapeutic effects and a substantial decrease in therapeutic effect.

In addition, because of the small diameter (~100 Ám) beam pumping focused on the surface of the active element of the laser dye (solid matrix) used a rotation system ensures the scanned area of the surface of the active element (to be collected in the form of separate concentric circles) of very small size. Therefore, in the laser dyes used a small part of the area of the active element, which significantly limits the lifetime (durability) of the device.

The technical essence of the invention is to improve the spectral and energy efficiency of the laser radiation during therapeutic effect while reducing the time of exposure and to increase the durability of the device.

This goal is achieved by the fact that the laser therapeutic apparatus contains basiccontrol laser visible range (second harmonic laser yttrium aluminate), the output of which has a polarizer return dichroic mirror and tunable to wavelengths of laser dyes in a solid matrix, and the channel noninvasive transmission of laser radiation on byobject.

In the best of the rotating plane of polarization thus, to the vector of the electric field E of the laser radiation of the visible range lying in the plane of the resonator tunable laser dye in a solid matrix, and return dichroic mirror which is transparent to visible ( = 534 nm) and deaf to the IR - spectrum ( = 1064 nm) of the pump radiation. The coincidence of vectors of linear polarization of the pump laser and the laser dye in a solid matrix and filtering the infrared radiation spectrum of the pump laser provides maximum spectral energy efficiency of the laser radiation apparatus.

Durability and service life of the active element is a dye in a solid matrix, made in the form of plane-parallel disk is provided by a Cam device type, performing the rotation of the active element together with his swing on the spiral of Archimedes with a constant linear velocity. This provides almost equal to the entire surface of the active element surface scan.

Using the proposed design of the laser therapeutic apparatus can significantly improve its spectral energy efficiency, in order to increase the time of exposure, the AK and therapeutic effects.

The drawing shows a functional structure of the device.

The device contains basiccontrol laser 1 visible range of radiation, such as laser yttrium aluminate, dichroic return mirror 2 and a polarizer 3, and tunable to wavelengths of laser dyes in a solid matrix 4 with rotation and scanning of the beam pump 5 and a system for the transmission of laser radiation on biological object 6 on the basis of a flexible fiber. All construction is made in a single body.

In a specific embodiment, the laser therapeutic apparatus polarizer made of crystalline quartz, size 3.5 mm x 10 mm x 10 mm, dichroic return mirror with a diameter of 20 mm and a thickness of 5 mm, and the solid matrix in the form of a disk with a diameter of 50 mm and 8 mm thick polymethyl methacrylate with uniformly distributed through its volume of organic dyes - rhodamine 6g, rhodamine C, oxazine 17, fentolamina 510, oxazine 1 or crystals Li F with stable F2+- centers. Optical pumping of the active element, a dye in a solid matrix that is installed at the Brewster angle to the optical axis of the Selection of the desired wavelength of the radiation apparatus is provided prismatic dispersion resonator laser 4, and reconstruction of the emission wavelength by turning the rear mirror in the plane of the resonator of the laser 4.

The device allows carrying out non-invasive literaturovedtsheskogo impact on the pathologic lesion in the wavelength range from 550 nm to 1050 nm pulses of short duration to 210-8with the pulse repetition frequency 1 Hz to 3 Hz and a pulse energy of 0.25 - 1.5 MJ.

Experimental samples of the device made in accordance with the claimed technical solution successfully passed clinical trials in the Main military Clinical hospital. N. N. Burdenko MORPH (radiological centre, a physiotherapy Department and intensive care unit), Central military research aviation hospital (physiotherapy Department) MORPH, Bashkir Oncology center, Ufa. Russian medical Academy of postgraduate education Ministry of health and the MP of the Russian Federation (radiological centre, Department of clinical radiology, Department of military field therapy), Russian scientific center for rehabilitation and physiotherapy MH and MP of the Russian Federation and confirmed the effect set forth in the description of the invention.

Sources of information

1. Alexandrov, M. T., Boikova R. A., Gurkin A. C., and others Use the dialogue of medical electronic devices, 1990, No. 3, S. 29-30.

3. USSR author's certificate N 1396325, class A 61 N 5/6 from 29.04. 1984

4. Certificate of utility model N 285, Bulletin of inventions and discoveries, No. 3, 1995 - the prototype.

Laser therapeutic apparatus contains laser of visible range, tunable laser dye in a solid state matrix system of its rotation and non-invasive device for the transmission of laser radiation on biological object, characterized in that the laser output of the visible range has a polarizer return dichroic mirror so that the vector of the linear polarized laser visible range coincides with the vector of the linear polarized tunable laser dye, while the cavity tunable laser dye contains a Cam device type, providing rotation of the active element in a solid matrix, together with his swing on the spiral of Archimedes with a constant linear velocity.

 

Same patents:

The invention relates to medicine, in particular to the treatment of ischemic heart disease

The invention relates to medicine, in particular to physiotherapy

The invention relates to medicine, namely to methods for treating electromagnetic radiation

The invention relates to medicine, namely to methods of treatment of trophic ulcers of low-intensity laser radiation
The invention relates to medicine, namely to dermatology
The invention relates to urology and is intended to be a comprehensive treatment of chronic urethritis, urogenital infections caused
The invention relates to medicine, namely to the rehabilitation of hemodynamic disturbances associated with physical activity in overload mode
The invention relates to urology and is intended for the integrated treatment endourethral warts
The invention relates to urology and is intended for the integrated treatment of strictures of the urethra, caused by urogenital infections

FIELD: medicine.

SUBSTANCE: method involves introducing 0.1-0.3 ml of photosensitizing gel preliminarily activated with laser radiation, after having removed neovascular membrane. The photosensitizing gel is based on a viscoelastic of hyaluronic acid containing khlorin, selected from group containing photolon, radachlorine or photoditazine in the amount of 0.1-2% by mass. The photosensitizing gel is in vitro activated with laser radiation having wavelength of 661-666 nm during 3-10 min with total radiation dose being equal to 100-600 J/cm2. The gel is introduced immediately after being activated. To compress the retina, vitreous cavity is filled with perfluororganic compound or air to be further substituted with silicon oil. The operation is ended with placing sutures on sclerotomy and conjunctiva areas. Compounds like chealon, viscoate or hyatulon are used as viscoelastic based on hyaluronic acid. Perfluormetylcyclohexylperidin, perfluortributylamine or perfluorpolyester or like are used as the perfluororganic compound for filling vitreous cavity.

EFFECT: excluded recurrences of surgically removed neovascular membrane and development of proliferative retinopathy and retina detachment; retained vision function.

3 cl, 5 dwg

FIELD: medicine.

SUBSTANCE: method involves making incision in conjunctiva and Tenon's capsule of 3-4 mm in size in choroid hemangioma projection to sclera 3-4 mm far from limb. Tunnel is built between sclera and Tenon's capsule to extrasclerally introduce flexible polymer magnetolaser implant through the tunnel to the place, the choroid hemangioma is localized, after performing transscleral diaphanoscopic adjustment of choroid hemangioma localization and size, under visual control using guidance beam. The implant has permanent ring-shaped magnet in the center of which a short focus scattering lens of laser radiator is fixed. The lens is connected to light guide in soft flexible envelope. The permanent implant magnet is axially magnetized and produces permanent magnetic field of 2-3 mTesla units intensity. It is arranged with its north pole turned towards the choroid hemangioma so that extrascleral implant laser radiator disposition. The other end of the implant is sutured to sclera 5-6 mm far from the limb with two interrupted sutures through prefabricated openings. The implant is covered with conjunctiva and relaxation sutures are placed over it. Light guide outlet is attached to temple using any known method. 0.1-1% khlorin solution is injected in intravenous bolus dose of 0.8-1.1 mg/kg as photosensitizer and visual control of choroid hemangioma cells fluorescence and fluorescent diagnosis methods are applied. After saturating choroid hemangioma with the photosensitizer to maximum level, transscleral choroid hemangioma laser radiation treatment is carried out via laser light guide and implant lens using divergent laser radiation at wavelength of 661-666 nm with total radiation dose being equal to 30-120 J/cm2. The flexible polymer magnetolaser implant is removed and sutures are placed on conjunctiva. Permanent magnet of the flexible polymer magnetolaser implant is manufactured from samarium-cobalt, samarium-iron-nitrogen or neodymium-iron-boron system material. The photosensitizer is repeatedly intravenously introduced at the same dose in 2-3 days after the first laser radiation treatment. Visual intraocular neoplasm cells fluorescence control is carried out using fluorescent diagnosis techniques. Maximum level of saturation with the photosensitizer being achieved in the intraocular neoplasm, repeated laser irradiation of the choroid hemangioma is carried out with radiation dose of 30-60 J/cm2.

EFFECT: enhanced effectiveness of treatment.

4 cl

FIELD: medicine.

SUBSTANCE: method involves creating tunnel between sclera and Tenon's capsule in intraocular neoplasm projection. Intraocular neoplasm localization and size is adjusted by applying transscleral diaphanoscopic examination method. 0.1-0.3 ml of photosensitizing gel based on viscoelastic of hyaluronic acid, selected from group containing chealon, viscoate or hyatulon, is transsclerally introduced into intraocular neoplasm structure using special purpose needle in dosed manner. The photosensitizing gel contains khlorin, selected from group containing photolon, radachlorine or photoditazine in the amount of 0.1-1% by mass. Flexible polymer magnetolaser implant is extrasclerally introduced into the built tunnel in intraocular neoplasm projection zone under visual control using guidance beam. The implant has permanent ring-shaped magnet axially magnetized and producing permanent magnetic field of 3-4 mTesla units intensity, in the center of which a short focus scattering lens of laser radiator is fixed. The lens is connected to light guide in soft flexible envelope. The implant is arranged with its north pole turned towards the intraocular neoplasm so that implant laser radiator lens is extrasclerally arranged in intraocular neoplasm projection zone. The implant light guide is sutured to sclera 5-6 mm far from the limb with single interrupted suture. The implant is covered with conjunctiva and relaxation sutures are placed over it. Light guide outlet is attached to temple using any known method. Visual control of intraocular neoplasm cells is carried out by applying fluorescence and fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, transscleral intraocular neoplasm laser radiation treatment is carried out via laser light guide and implant lens using divergent laser radiation at wavelength of 661-666 nm. The treatment course being over, the flexible polymer magnetolaser implant is removed and sutures are placed on conjunctiva. Permanent magnet of the flexible polymer magnetolaser implant is manufactured from samarium-cobalt, neodymium-iron-boron or samarium-iron-nitrogen. 0.1-1% khlorin solution as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is additionally intravenously introduced in 2-3 days at a dose of 0.8-1.1 mg/kg and repeated laser irradiation of the intraocular neoplasm is carried out with radiation dose of 30-45 J/cm2 15-20 min later during 30-90 s.

EFFECT: complete destruction of neoplasm; excluded its further growth.

4 cl

FIELD: medicine.

SUBSTANCE: method involves applying transscleral diaphanoscopic examination method for adjusting intraocular neoplasm localization and size. Rectangular scleral pocket is built 2/3 times as large as sclera thickness which base is turned from the limb. Several electrodes manufactured from a metal of platinum group are introduced into intraocular neoplasm structure via the built scleral pocket. Next to it, intraocular neoplasm electrochemical destruction is carried out in changing electrodes polarity with current intensity of 100 mA during 1-10 min, and the electrodes are removed. Superficial scleral flap is returned to its place and fixed with interrupted sutures. 0.1-2% aqueous solution of khlorin as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is intravenously introduced at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells is carried out by applying fluorescence and fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, transpupillary laser radiation of 661-666 nm large wavelength is applied at a dose of 30-120 J/cm2. the operation is ended with placing sutures on conjunctiva. Platinum, iridium or rhodium are used as the metals of platinum group. The number of electrodes is equal to 4-8. 0.1-1% khlorin solution, selected from group containing photolon, radachlorine or photoditazine, is additionally repeatedly intravenously introduced in 2-3 days at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells is carried out by applying fluorescence and fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, repeated laser irradiation of the intraocular neoplasm is carried out with radiation dose of 30-45 J/cm2.

EFFECT: complete destruction of neoplasm; excluded tumor recurrence; reduced risk of tumor cells dissemination.

3 cl, 3 dwg

FIELD: medicine.

SUBSTANCE: the present innovation deals with treating vascular cutaneous neoplasms, such as nevus flammeus and gemangiomas. Light-thermal impact at energy ranged 39-47 J/sq. cm should be performed in two stages, and between them, 2-3 wk after the onset of vascular resistance at the first stage one should perform beta-therapy daily for 2-3 d at single dosage being 20 g. Then, 3 wk later it is necessary to conduct the second stage of light-thermal impact by starting at energy value being 42 J/sq. cm, not less. The method enables to shorten therapy terms due to applying combined method to affect vascular cutaneous neoplasms.

EFFECT: higher therapeutic and cosmetic effect.

1 ex

FIELD: medicine.

SUBSTANCE: method involves intravitreously introducing two electrodes into intraocular neoplasm after carrying out vitrectomy and retinotomy to expose the intraocular neoplasm. The electrodes are manufactured from platinum group metal. Electrochemical destruction is carried out with current intensity of 100 mA during 1-10 min or 10 mA during 10 min in changing electrodes polarity and their position in the intraocular neoplasm space, and the electrodes are removed. 0.1-1% aqueous solution of khlorin as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is intravenously introduced at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells fluorescence is carried out by applying fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, intravitreous laser radiation is carried out in parallel light beam of wavelength equal to 661-666 nm is applied at a dose of 30-120 J/cm2.The transformed retina and tumor destruction products are intravitreally removed. Boundary-making endolasercoagulation of retinotomy area is carried out after having smoothed and compressed retina with perfluororganic compound. The operation is finished with placing sutures on sclerotomy and conjunctiva. Platinum, iridium or rhodium are used as the platinum group metals. Another embodiment of the invention involves adjusting position and size of the intraocular neoplasm in trans-scleral diaphanoscopic way. Rectangular scleral pocket is built above the intraocular neoplasm to 2/3 of sclera thickness with its base turned away from limb. Several electrodes are introduced into intraocular neoplasm structure via the built bed. The electrodes are manufactured from platinum group metal. Electrochemical destruction is carried out with the same current intensity in changing electrodes polarity and their position in the intraocular neoplasm space, and the electrodes are removed. Superficial scleral flat is returned to its place and fixed with interrupted sutures. 0.1-1% aqueous solution of khlorin as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is intravenously introduced at a dose of 0.8-1.1 mg/kg after having carried out vitrectomy and retinotomy. Visual control of intraocular neoplasm cells fluorescence is carried out by applying fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, intravitreous laser radiation is carried out in parallel light beam of wavelength equal to 661-666 nm is applied at a dose of 30-120 J/cm2. The transformed retina and tumor destruction products are intravitreally removed using vitreotome. Boundary-making endolasercoagulation of retinotomy area is carried out after having smoothed and compressed retina with perfluororganic compound. The operation is finished with placing sutures on sclerotomy and conjunctiva. Platinum, iridium or rhodium are used as the platinum group metals. The number of electrodes is equal to 4-8.

EFFECT: reduced risk of metastasizing.

4 cl, 13 dwg

FIELD: medicine.

SUBSTANCE: method involves building tunnel to posterior eyeball pole in inferoexterior and superexterior quadrants. The tunnel is used for implanting flexible polymer magnetolaser implant to the place, the subretinal neovascular membrane is localized. The implant has a permanent magnet shaped as a cut ring and is provided with drug delivery system and a short focus scattering lens of laser radiator connected to light guide. The permanent implant magnet is axially magnetized and produces permanent magnetic field of 5-7 mTesla units intensity. It is arranged with its north pole turned towards sclera at the place of the subretinal neovascular membrane projection with extrascleral arrangement of laser radiator lens membrane being provided in the subretinal neovascular membrane projection area. The other implant end is sutured to sclera 5-6 mm far from the limb via holes made in advance. The implant is covered with conjunctiva and retention sutures are placed thereon. Light guide and drug supply system lead is attached to temple with any known method applied. Drugs are supplied via the implant drug supply system in retrobulbary way in any order. Triombrast is given in the amount of 0,4-0,6 ml and dexamethasone or dexone in the amount of 0,4-0,6 ml during 3-4 days every 12 h. 0.1-1% aqueous solution of khlorin is intravenously introduced at the third-fourth day after setting the implant as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, at a bolus dose of 0.8-1.1 mg/kg. Visual control of subretinal neovascular membrane cells fluorescence is carried out by applying fluorescent diagnosis methods. After saturating the subretinal neovascular membrane with the photosensitizer to maximum saturation level, intravitreous, transretinal laser radiation of 661-666 nm large wavelength is applied at general dose of 30-120 J/cm2. The flexible polymer magnetolaser implant is removed and sutures are placed on conjunctiva. Permanent magnet of the flexible polymer magnetolaser implant is manufactured from samarium-cobalt, samarium-iron-nitrogen or neodymium-iron-boron system material. The photosensitizer is repeatedly intravenously introduced at the same dose in 2-3 days after the first laser radiation treatment. Visual intraocular neoplasm cells fluorescence control is carried out using fluorescent diagnosis techniques. Maximum level of saturation with the photosensitizer being achieved in the subretinal neovascular membrane via laser light guide and implant lens, repeated laser irradiation of the subretinal neovascular membrane is carried out with radiation dose of 30-60 J/cm2.

EFFECT: accelerated subretinal edema and hemorrhages resorption; regression and obliteration of the subretinal neovascular membrane; prolonged vision function stabilization.

6 cl

FIELD: medicine.

SUBSTANCE: method involves filling vitreous cavity with perfluororganic compound. Two electrodes manufactured from platinum group metal are intravitreally, transretinally introduced into intraocular neoplasm. Electrochemical destruction is carried out with current intensity of 10-100 mA during 1-10 min in changing electrodes polarity and their position in the intraocular neoplasm space, and the electrodes are removed. 0.1-1% aqueous solution of khlorin as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is intravenously introduced at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells fluorescence is carried out by applying fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, intravitreous, transretinal laser radiation of 661-666 nm large wavelength is applied at a dose of 30-120 J/cm2 in perfluororganic compound medium. The transformed retina and tumor destruction products are intravitreally removed with perfluororganic compound volume being compensated with its additional introduction. Boundary-making endolasercoagulation of retinotomy area is carried out. The perfluororganic compound is substituted with silicon oil. The operation is ended in placing sutures over sclerotmy areas and over conjunctiva. Perfluormetylcyclohexylperidin, perfluortributylamine or perfluorpolyester or like are used as the perfluororganic compound for filling vitreous cavity. Platinum, iridium or rhodium are used as the platinum group metals.

EFFECT: complete destruction of neoplasm; reduced dissemination risk.

6 cl, 12 dwg

FIELD: medicine, applicable for stopping of pains of various nature.

SUBSTANCE: the device has a quantum-mechanical oscillator located in a casing, magnet, vessel for medicinal agent and a hollow cylinder. The magnet is installed between the oscillator and the vessel. Positioned in the vessel is a hollow cylinder having through holes on its surface.

EFFECT: quick and absolute anestesia.

2 ex, 1 dwg

FIELD: medicine.

SUBSTANCE: method involves administering laser radiation therapy once a day using low intensity pulsating radiation of wavelength equal to 890nmand power density of 0.03 mW/cm2. Injured organ projection to frontal abdominal wall is exposed to radiation at the first laser therapy stage in two fields acting upon each field for 2 min with radiation pulse succession frequency equal to 80 Hz in applying stable contact-type method. Total treatment dose on two fields is equal to 0.008 J/cm2. The second laser therapy stage begins immediately after having finished the first one in applying radiation along the large intestine path using labile contact-type method in a way that radiation pulse succession frequency equal to 80 Hz is applied first during 1 min and then frequencies of 600, 150 and 300 Hz are applied also during 1 min, respectively. Total treatment dose is equal to 0.032 J/cm2 at the second stage. Total treatment dose is equal to 0.04 J/cm2 at both stages.

EFFECT: enhanced effectiveness in inhibiting dysbacteriosis; reduced frequency of postoperative complications.

Up!